MOTS-c peptide: the unfinished inventory

What is MOTS-c?

I opened the MOTS-c peptide file for its mitochondrial address. Its instructions sit inside mitochondrial DNA, tucked into the region called 12S ribosomal RNA. Mitochondria help cells make energy; this small piece of their genome also encodes a 16-amino-acid signal involved in glucose control. That is a more interesting beginning than another list of possible benefits.

The founding report appeared in 2015. Treated mice resisted the insulin resistance and excess weight gain associated with a high-fat diet, with skeletal muscle emerging as a principal target. In cultured cells, MOTS-c changed the chemistry that feeds into AMPK, a cellular energy sensor. The later work on movement into the nucleus under stress adds an unexpected destination to that mitochondrial origin.

The mitochondrial origin drew me in; the muscle experiments gave the curiosity some substance.

MOTS-c benefits in the animal papers

The animal inventory includes improved glucose handling, physical performance and responses to metabolic stress. In the 2021 mouse performance study, MOTS-c increased treadmill running capacity, grip strength and gait performance in aged mice. The 2019 work in mice after ovary removal examined fat-tissue metabolism under estrogen deficiency. Each experiment has its own animals and its own problem.

My enthusiasm runs highest where the result is concrete: a mouse runs farther, a muscle cell takes up more glucose, a protein binds another molecule. The phrase “anti-aging” gathers these very different outcomes into a much larger claim. The review of mitochondrial peptides and aging provides context; the cited literature still has no completed human treatment trial establishing MOTS-c benefit or safety.

The research inventory follows the experiments in sequence. The blood sugar and heart page puts the metabolic claims under closer inspection.

Human MOTS-c blood levels

Here is the awkward entry. Studies of boys with obesity and insulin resistance and children with obesity and vascular-function measurements found lower circulating MOTS-c. Yet a cohort of 94 people receiving chronic hemodialysis associated higher levels with more deaths or non-fatal cardiovascular events.

Those populations differ enormously. None received MOTS-c treatment. A universal health score seems far too neat to me: the dialysis finding demands room in the inventory, even when it spoils an appealing “more is better” story. Adding MOTS-c to the usual risk assessment in that study did not improve prediction enough to guide care.

The question worth pursuing is why the associations change with the setting. The existing studies leave that answer open.

Stress, metabolism and aging

The 2023 review of MOTS-c mechanisms brings together the folate-cycle work, stress responses and aging research. It is a useful place to see how far the biological questions have spread. A broad research programme can be exciting while the practical human questions remain unanswered.

The animal dosage record holds the experimental amounts and the missing human half-life. Legal status covers the dated FDA material. For questions about side effects, subjective experiences and muscle growth, start with the FAQ.